Abstract: The disclosure relates to compounds that demonstrate efficacy in blocking PACAP receptors (e.g. PAC1) and associated methods of treating neurological diseases or disorders using the disclosed compounds. The neurological diseases or disorders include, but are not limited to, stress-related diseases (e.g. chronic stress, post-traumatic stress disorder (PTSD), panic disorder, anxiety, or general anxiety disorder), pain-related diseases (e.g. chronic pain, primary headache disorders, or migraines), or addiction (e.g. addiction to a substance (e.g. addiction to cocaine, amphetamines, methamphetamine, methylphenidate, nicotine, alcohol, prescription medication, marijuana, tobacco, or an opioid selected from heroin, fentanyl, codeine, hydrocodone, morphine, oxycodone, hydromorphone, and methadone)).

Abstract: The present invention has to do with a method and system for peritoneal dialysis catheter weighted anchors. The peritoneal dialysis catheter weighted anchors can be inserted and retrieved using standard techniques and available insertion/retrieval systems. The peritoneal dialysis catheter weighted anchors can be attached and secured to all types of PD catheters as an ancillary anchor device.

Abstract: A membrane filtration cell is provided which includes a fluid passageway and a filtration membrane positioned within the passageway, the filtration membrane dividing the fluid passageway into two chambers, a retentate chamber and a permeate chamber. A first electrode is positioned in the retentate chamber and a second electrode is positioned in the permeate chamber, where the first electrode and the second electrode are configured to apply an electric field across the filtration membrane. The membrane filtration cell also includes an acoustic device configured to apply an acoustic field across the retentate chamber, where the synergistic combination of the electric field and the acoustic field prevents fouling on the filtration membrane.

Abstract: Described herein are antibodies or variants thereof that specifically bind to coronavirus antigens, such as SARS-CoV-2 antigens. The antibodies can be neutralizing antibodies. Also provided are methods of using the antibodies, including methods of treating a subject infected with SARS-CoV-2, and methods of diagnosing a subject infected with SARS-CoV-2.

Abstract: Described herein are antibodies or variants thereof that specifically bind to coronavirus antigens, such as SARS-CoV-2 antigens. The antibodies can be neutralizing antibodies. Also provided are methods of using the antibodies, including methods of treating a subject infected with SARS-CoV-2, and methods of diagnosing a subject infected with SARS-CoV-2.

Abstract: The present invention has to do with a method and system for preformed peritoneal dialysis (PD) catheter weighted anchors. The peritoneal dialysis catheter weighted anchors can be inserted and retrieved using standard techniques and available insertion/retrieval systems. The peritoneal dialysis catheter weighted anchors can be attached and secured to all types of PD catheters as an ancillary anchor device.

Abstract: The invention features isolated protein complexes and compositions and methods for use thereof. In embodiments, the isolated protein complexes are used for treating conditions associated with reperfusion injury, hypofusion, and/or low/no-reflow. The isolated protein complexes comprise a fusion protein complexed with basic fibroblast growth factor (FGF2), hepatocyte growth factor (HGF), or vascular endothelial growth factor (VEGF). The fusion protein contains an immunoglobulin G (IgG) Fc domain fused to a polypeptide (e.g., Jagged1, a growth factor, or a cytokine).

Abstract: Catheters, systems, and related methods for optimized for mapping, minimizing, and treating cardiac fibrillation in a patient, including an array of at least one stacked electrode pair, each electrode pair including a first electrode and a second electrode, wherein each electrode pair is configured to be orthogonal to a surface of a cardiac tissue substrate, wherein each first electrode is in contact with the surface to record a first signal, and wherein each second electrode is separated from the first electrode by a distance which enables the second electrode to record a second signal, wherein the catheter is configured to obtain one or more measurements from at least a first signal and a second signal in response to electrical activity in the cardiac tissue substrate indicative of a number of electrical circuit cores and distribution of the electrical circuit cores for a duration across the cardiac tissue substrate.

Abstract: According to some aspects, a cardiac pacemaker for implantation within a subject is provided, the pacemaker including a housing, at least one sensor configured to detect an activity level of the subject, and at least one processor coupled to the sensor configured to detect inactivity of the subject based on output from the at least one sensor, produce a first signal configured to increase the heart rate of the subject to a first heart rate during a first time period, wherein the first heart rate is above a resting heart rate and below 100 beats per minute, and in response to determining that the first time period has elapsed, producing a second signal configured to increase the heart rate of the subject to a second heart rate during a second time period, wherein the second heart rate is between 100 and 140 beats per minute.

Abstract: The invention features methods and compositions for treating a reperfusion injury, hypofusion, ischemic injury, and/or low/no-reflow. In embodiments, the compositions contain complexes containing a basic fibroblast growth factor (FGF2) and an immunoglobulin G (IgG) polypeptide, or fragments thereof. In embodiments, the complexes further contain a hepatocyte growth factor (HGF) polypeptide, a vascular endothelial growth factor (VEGF) polypeptide, or fragments thereof.

Abstract: Compositions and methods involving protein disulfide isomerase (PDI) inhibitors, such as protein disulfide isomerase A3 (PDIA3) inhibitory compounds, for human coronavirus, such as severe acute respiratory syndrome (SARS) virus (e.g., SARS-CoV-2), therapies are disclosed herein.

Abstract: The present invention generally relates to systems and methods for treating certain oxidative stress conditions. In one aspect, compositions and methods of the invention can be used to treat a subject having an oxidative stress condition, for example, a subject having pulmonary fibrosis. In some embodiments, an inhibitor of ERp57 (for example, thiomuscimol) and/or an inhibitor of GSTP (for example, TLK-199) may be used to treat the subject. Also provided in certain aspects of the present invention are kits for such therapies, methods for promoting such therapies, and the like.

Abstract: Demand response methodologies for primary frequency response (PFR) for under or over frequency events. Aspects of the present disclosure include methods for controlling a fleet of distributed energy resources equipped for PFR and quantifying in real time an amount of primary frequency control capacity available in the fleet. In some examples, the DERs may be configured to consume and discharge electrical energy in discrete energy packets and be equipped with a frequency response local control law that causes each DER to independently and instantaneously interrupt an energy packet in response to local frequency measurements indicating a grid disturbance event has occurred.

Abstract: Methods and kits for detecting cancer-associated miRNA are disclosed herein. Methods of identifying and treating a human patient at risk for cancer are also disclosed herein.

Abstract: Compositions and methods involving protein disulfide isomerase (PDI) inhibitors, such as protein disulfide isomerase A3 (PDIA3) inhibitory compounds, for human coronavirus, such as severe acute respiratory syndrome (SARS) virus (e.g., SARS-CoV-2), therapies are disclosed herein.

Abstract: A nanobiocatalytic membrane for a filtration system is provided which includes a filtration membrane and a plurality of nanobiocatalyst nanoparticles associated with the membrane, each of the nanobiocatalyst nanoparticles including a core, a coating at least partially surrounding the core, and a plurality of nanobiocatalysts coupled to the coating. Each of the plurality of nanobiocatalysts includes an antibacterial nanoparticle comprising bismuth, and a quorum quenching agent coupled to the antibacterial nanoparticle. A nanobiocatalyst nanoparticle for use with a water purification system is also provided. A method of forming a nanobiocatalytic membrane for a filtration system and a method of using a nanobiocatalytic membrane in a filtration system are also provided.

Abstract: This invention relates to methods of administering compounds containing selenium, selenocysteine, or a selenocysteine peptide to treat, for example, conditions associated with selenium deficiency, or ferroptoptic, parthanototic, and endoplasmic reticulum stress, and/or cancer. The methods of treatment may activate or inhibit (via TFAP2C and Sp1 proteins) the adaptive homeostatic response of the selenome. The compounds may contain a targeting sequence that causes them to be delivered to specific organs and/or tissues. The compounds may be administered, for example, orally, intranasally, intravenously, or by a minimally invasive catheter or BrainPath.

Abstract: The invention features compositions featuring (a) one or more of connective tissue growth factor (CTGF) and human C-terminal CTGF peptide; and (b) one or more of insulin and IGF-1; and methods of using such compositions to reduce cardiac tissue damage associated with an ischemic event or to enhance engraftment of a cell in a cardiac tissue.

Abstract: The invention relates, in part, to methods and compositions that are useful to modulate metabolic function of cells in vivo or in vitro. In some aspects the invention includes methods and/or compositions that increase metabolism in cells, tissues, organs, and/or subjects. In certain aspects the invention includes methods and/or compositions useful to decrease metabolism in cells, tissues, organs, and/or in subjects.

Abstract: Compositions and methods are provided for determining platelet reactivity where the levels of Fc?RIIa on the surface of platelets is measured and if the levels of Fc?RIIa are greater than a reference value, the platelets have enhanced reactivity.